Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Bauer

Showing results (311-320 of 408) with videos related to

Pageof 41
Sort By:
Pediatric Blood & Cancer|February 27, 2018
Recurrence of Ewing sarcoma: Is detection by imaging follow-up protocol associated with survival advantage?Melina Heinemann, Andreas Ranft, Thorsten Langer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 19, 2026
<sup>90</sup>Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort AnalysisHelena Lanzafame, Ilektra A Mavroeidi, Kim M Pabst, et al.
Ebiomedicine|November 7, 2018
Dual-center, dual-platform microRNA profiling identifies potential plasma biomarkers of adult temporal lobe epilepsyRana Raoof, Sebastian Bauer, Hany El Naggar, et al.
Scientific Reports|May 27, 2021
Wada test results contribute to the prediction of change in verbal learning and verbal memory function after temporal lobe epilepsy surgeryNadine Conradi, Friederike Rosenberg, Susanne Knake, et al.
JAMA Oncology|March 24, 2017
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical TrialHeikki Joensuu, Eva Wardelmann, Harri Sihto, et al.
The Lancet. Oncology|September 23, 2011
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypesPatrick Schöffski, Isabelle Laure Ray-Coquard, Angela Cioffi, et al.
The Oncologist|March 31, 2026
MyCODE: A prospective evaluation of Lay-language Molecular Tumor Board Protocols in Precision OncologyIna Pretzell, Anke Fleischhauer, Ilektra Mavroeidi, et al.
Cancer|March 31, 2021
Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomasInga-Marie Schaefer, Meijun Z Lundberg, Elizabeth G Demicco, et al.
Cancer Discovery|September 25, 2020
Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase DomainSusanne Grunewald, Lillian R Klug, Thomas Mühlenberg, et al.
The Oncologist|December 10, 2020
Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal TumorsCissimol P Joseph, Sarah N Abaricia, Michelle A Angelis, et al.
Pageof 41

Showing results (311-320 of 408) with videos related to

Sort By:
Pageof 41
Pediatric Blood & Cancer|February 27, 2018
Recurrence of Ewing sarcoma: Is detection by imaging follow-up protocol associated with survival advantage?Melina Heinemann, Andreas Ranft, Thorsten Langer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 19, 2026
<sup>90</sup>Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort AnalysisHelena Lanzafame, Ilektra A Mavroeidi, Kim M Pabst, et al.
Ebiomedicine|November 7, 2018
Dual-center, dual-platform microRNA profiling identifies potential plasma biomarkers of adult temporal lobe epilepsyRana Raoof, Sebastian Bauer, Hany El Naggar, et al.
Scientific Reports|May 27, 2021
Wada test results contribute to the prediction of change in verbal learning and verbal memory function after temporal lobe epilepsy surgeryNadine Conradi, Friederike Rosenberg, Susanne Knake, et al.
JAMA Oncology|March 24, 2017
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical TrialHeikki Joensuu, Eva Wardelmann, Harri Sihto, et al.
The Lancet. Oncology|September 23, 2011
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypesPatrick Schöffski, Isabelle Laure Ray-Coquard, Angela Cioffi, et al.
The Oncologist|March 31, 2026
MyCODE: A prospective evaluation of Lay-language Molecular Tumor Board Protocols in Precision OncologyIna Pretzell, Anke Fleischhauer, Ilektra Mavroeidi, et al.
Cancer|March 31, 2021
Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomasInga-Marie Schaefer, Meijun Z Lundberg, Elizabeth G Demicco, et al.
Cancer Discovery|September 25, 2020
Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase DomainSusanne Grunewald, Lillian R Klug, Thomas Mühlenberg, et al.
The Oncologist|December 10, 2020
Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal TumorsCissimol P Joseph, Sarah N Abaricia, Michelle A Angelis, et al.
Pageof 41